🇺🇸 FDA
Patent

US 8431154

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

granted A61KA61K31/166A61K31/44

Quick answer

US patent 8431154 (Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient) held by TAKEDA GMBH expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TAKEDA GMBH
Grant date
Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
38
CPC classes
A61K, A61K31/166, A61K31/44, A61K9/0002, A61K9/0053